Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
Kay Emerson was the first person in Wisconsin and one of the first in the United States to be successfully treated for phenylketonuria (PKU), a condition in which the body fails to break down the amino acid phenylalanine, causing a buildup.
Research and clinical services go hand in hand. One can’t effectively work without the other.
When President Kennedy made his inaugural speech in 1961, there was no mention of initiatives on intellectual and developmental disabilities (IDDs). Yet, the efforts by his administration and the Kennedy family to improve the lives of individuals with disabilities and their families are one of their most enduring legacies. The Waisman Center, University of Wisconsin-Madison bears the indelible fingerprints of those efforts.
Fifty-one years ago today, President John F. Kennedy sent a telegram to Harry Waisman congratulating him on the dedication of the Joseph P. Kennedy Jr. Laboratories. Two days later, the president was dead. Marsha Mailick recounts the connection between the Kennedys and what would become the Waisman Center.
Kay Emerson, one of the first patients treated successfully for the PKU disorder in the United States, talks about researcher Dr. Harry Waisman.
In a rare look back in time, we’re given a glimpse into the early research and community outreach of Harry A. Waisman, MD, PhD, one of the lead researchers of Phenylketonuria (PKU), an inherited condition caused by an accumulation of the amino acid phenylalanine.
Stu Levitan, Isthmus Wednesday, Nov. 20, 1963 Cloudy, humid, high 48 President John F. Kennedy begins his last full day in the White House with a Western Union telegram to UW-Madison President Fred Harvey Harrington. Kennedy congratulates Dr. Harry Waisman and his colleagues at the UW Orthopedic Children’s Hospital on that afternoon’s dedication of the …
It has always been a challenge to describe the Waisman Center on the University of Wisconsin–Madison campus.
